D.A. Davidson Acts as Exclusive Financial Advisor to Turnspire Capital Partners for Debt Financing in Support of Turnspire’s Acquisition of Pharmachem
D.A. Davidson & Co. has acted as the exclusive financial advisor to Turnspire Capital Partners for an asset-backed credit facility to finance Turnspire's acquisition of Pharmachem Innovations, from Ashland Inc. (NYSE: ASH). Pharmachem is a leading provider of proprietary nutrition ingredients and custom formulation services for the nutrition market. The company has approximately 500 employees across four production facilities in New Jersey, Utah, and Mexico. Ilya Koffman, Managing Partner at Turnspire, stated that the new capital structure will support Pharmachem's growth plans. This transaction showcases D.A. Davidson's capability in arranging financings for financial sponsors.
D.A. Davidson & Co. ha agito come advisor finanziario esclusivo per Turnspire Capital Partners per un credito garantito da attivi destinato a finanziare l'acquisizione di Pharmachem Innovations da parte di Turnspire, da Ashland Inc. (NYSE: ASH). Pharmachem è un fornitore leader di ingredienti nutrizionali proprietari e servizi di formulazione personalizzata per il mercato della nutrizione. L'azienda conta circa 500 dipendenti in quattro stabilimenti produttivi nel New Jersey, Utah e Messico. Ilya Koffman, Managing Partner di Turnspire, ha dichiarato che la nuova struttura di capitale supporterà i piani di crescita di Pharmachem. Questa transazione dimostra la capacità di D.A. Davidson di organizzare finanziamenti per sponsor finanziari.
D.A. Davidson & Co. ha actuado como asesor financiero exclusivo para Turnspire Capital Partners por un facilidad de crédito respaldada por activos para financiar la adquisición de Pharmachem Innovations por parte de Turnspire, de Ashland Inc. (NYSE: ASH). Pharmachem es un proveedor líder de ingredientes nutricionales patentados y servicios de formulación personalizada para el mercado de la nutrición. La empresa cuenta con aproximadamente 500 empleados en cuatro instalaciones de producción en Nueva Jersey, Utah y México. Ilya Koffman, Socio Director de Turnspire, declaró que la nueva estructura de capital apoyará los planes de crecimiento de Pharmachem. Esta transacción demuestra la capacidad de D.A. Davidson para organizar financiamientos para patrocinadores financieros.
D.A. Davidson & Co.는 Turnspire Capital Partners의 독점 재정 자문사로 활동했으며, Turnspire가 Ashland Inc. (NYSE: ASH)로부터 Pharmachem Innovations을 인수하기 위한 자산 담보 신용 시설을 조달했습니다. Pharmachem은 영양 시장을 위한 독창적인 영양 성분 및 맞춤형 제형 서비스의 주요 공급업체입니다. 이 회사는 뉴저지, 유타 및 멕시코에 있는 네 개의 생산 시설에서 약 500명의 직원을 고용하고 있습니다. Turnspire의 관리 파트너인 Ilya Koffman은 새로운 자본 구조가 Pharmachem의 성장 계획을 지원할 것이라고 밝혔습니다. 이 거래는 D.A. Davidson이 재정 후원자를 위한 자금을 조달하는 능력을 보여줍니다.
D.A. Davidson & Co. a agi comme conseiller financier exclusif pour Turnspire Capital Partners pour une facilité de crédit adossée à des actifs afin de financer l'acquisition de Pharmachem Innovations par Turnspire, auprès d'Ashland Inc. (NYSE: ASH). Pharmachem est un fournisseur de premier plan d'ingrédients nutritionnels propriétaires et de services de formulation sur mesure pour le marché de la nutrition. L'entreprise compte environ 500 employés répartis sur quatre sites de production dans le New Jersey, l'Utah et le Mexique. Ilya Koffman, associé directeur chez Turnspire, a déclaré que la nouvelle structure de capital soutiendrait les plans de croissance de Pharmachem. Cette transaction met en avant la capacité de D.A. Davidson à organiser des financements pour des sponsors financiers.
D.A. Davidson & Co. hat als exklusiver Finanzberater für Turnspire Capital Partners fungiert, um eine wertgesicherte Kreditfazilität zur Finanzierung der Übernahme von Pharmachem Innovations durch Turnspire von Ashland Inc. (NYSE: ASH) bereitzustellen. Pharmachem ist ein führender Anbieter von proprietären Nährstoffzutaten und maßgeschneiderten Formulierungsdiensten für den Ernährungsmarkt. Das Unternehmen hat etwa 500 Mitarbeiter in vier Produktionsstätten in New Jersey, Utah und Mexiko. Ilya Koffman, Managing Partner bei Turnspire, erklärte, dass die neue Kapitalstruktur die Wachstumspläne von Pharmachem unterstützen wird. Diese Transaktion zeigt die Fähigkeit von D.A. Davidson, Finanzierungen für finanzielle Sponsoren zu arrangieren.
- Acquisition of Pharmachem Innovations, a leading provider in the nutrition market
- Secured asset-backed credit facility for financing the acquisition
- Pharmachem has a broad portfolio of active ingredients and formulation aids
- Company offers custom formulation and contract manufacturing capabilities
- Pharmachem has 500 employees and four production facilities across three locations
- None.
Insights
Turnspire Capital Partners' acquisition of Pharmachem from Ashland Inc. represents a significant move in the nutraceuticals sector. The asset-backed credit facility, arranged by D.A. Davidson, provides Turnspire with the necessary capital to execute this strategic carve-out. This transaction highlights the ongoing trend of private equity firms targeting specialized segments within larger corporations.
From an investor's perspective, this deal could potentially unlock value in Pharmachem by allowing for more focused management and growth strategies. The company's diverse portfolio of nutrition ingredients and custom formulation services positions it well in the growing health and wellness market. However, investors should monitor how Turnspire manages the transition and implements its growth plans, as carve-outs can be complex to execute successfully.
The nutraceuticals market is experiencing robust growth, driven by increasing consumer focus on health and wellness. Pharmachem's acquisition by Turnspire could be timely, allowing for agile responses to market trends. With 500 employees and facilities across the US and Mexico, Pharmachem has a solid foundation for expansion.
Investors should note the potential for innovation and market share growth under new ownership. However, challenges may arise in integrating operations and maintaining customer relationships post-separation from Ashland. The success of this acquisition will likely depend on Turnspire's ability to leverage Pharmachem's existing capabilities while introducing new growth initiatives in a competitive landscape.
D.A. Davidson & Co. announced today that it served as exclusive financial advisor to Turnspire Capital Partners LLC on an asset-backed credit facility to finance Turnspire’s acquisition of Pharmachem Innovations, LLC, the former nutraceuticals business of Ashland Inc. (Graphic: Business Wire)
“We appreciate the D.A. Davidson team’s efforts in securing an attractive financing package for a complicated carve-out transaction, which enabled us to complete diligence and close the acquisition,” said Ilya Koffman, Managing Partner at Turnspire. “The new capital structure will help us achieve our growth plans for Pharmachem.”
Pharmachem is a leading provider of proprietary nutrition ingredients and custom formulation services that supplies a broad portfolio of both active ingredients and formulation aids to nutritional product companies. The Company also offers custom formulation and contract manufacturing capabilities for the nutrition market, handling everything from formula design and ingredient sourcing to finished product manufacturing. Pharmachem has approximately 500 employees located at four production facilities in
“We are pleased to have worked with the Turnspire team to arrange and place the acquisition financing to support Turnspire’s acquisition of Pharmachem,” commented Yaron Redlich, Head of Financial Sponsors Group at D.A. Davidson.
“This transaction demonstrates our Debt Advisory team’s capability set in arranging an array of financings for financial sponsors,” said Amy Johnson, Head of Debt Advisory at D.A. Davidson.
About Turnspire Capital Partners
Turnspire Capital Partners invests in high-quality businesses that have reached strategic, financial or operational inflection points and stand to benefit from our hands-on, operationally focused approach. Turnspire’s investment philosophy is predicated on creating value through operational improvements rather than through financial leverage. Turnspire strives to make each of its companies best-in-class in their respective industry niche, and then to grow the businesses through organic initiatives or strategic acquisitions.
About D.A. Davidson Companies
D.A. Davidson Companies is an employee-owned financial services firm offering a range of financial services and advice to individuals, corporations, institutions and municipalities nationwide. Founded in 1935 with corporate headquarters in
Subsidiaries include: D.A. Davidson & Co., a full-service investment firm providing wealth management, investment banking, equity and fixed income capital markets services, and advice; Davidson Investment Advisors, a professional asset management firm; and D.A. Davidson Trust Company, a trust and wealth management company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240918901821/en/
Media Contact
Emily Roy
Prosek for D.A. Davidson
(646) 818-9232
eroy@prosek.com
Source: D.A. Davidson & Co.
FAQ
What is the purpose of Turnspire Capital Partners' acquisition of Pharmachem Innovations from Ashland Inc. (ASH)?
How many employees and facilities does Pharmachem Innovations have after being acquired from Ashland Inc. (ASH)?
What services does Pharmachem Innovations offer in the nutrition market?
How did D.A. Davidson assist in Turnspire Capital Partners' acquisition of Pharmachem from Ashland Inc. (ASH)?
